Introduction {#Sec1}
============

Alzheimer's disease (AD), the most common form of dementia in the elderly, is characterized by two neuropathological hallmarks: senile plaques, which are composed of Aβ peptides, and neurofibrillary tangles, which are composed of hyperphosphorylated tau protein. The disease was first described in 1907 by Alois Alzheimer^[@CR1]^, who observed these two pathological hallmarks in patients' brains. Aβ peptides are derived from sequential proteolytic cleavage of the amyloid precursor protein (APP). While the non-amyloidogenic pathway involves sequential cleavage of full-length APP by the α-secretases and γ-secretase, the amyloidogenic pathway causing the production of Aβ peptides requires the cleavage of full-length APP by the β-secretase BACE1 and the γ-secretase^[@CR2]^. Multiple lines of evidence suggest that overproduction of Aβ results in neuronal dysfunction and, finally, in neuronal loss^[@CR3]^. The second pathological hallmark of AD, neurofibrillary tangles, are mainly composed of hyperphosphorylated tau protein^[@CR4],[@CR5]^. Tau is a microtubule-associated protein that stimulates and stabilizes microtubule assembly. Upon hyperphosphorylation, tau dissociates from microtubules, resulting in microtubule destabilization and neuronal death. The main tau phosphatase is protein phosphatase 2A (PP2A), which is capable of dephosphorylating tau at AD-relevant phospho-sites^[@CR6]^.

As we have shown previously, the MID1-PP2A protein complex regulates the phosphorylation of tau^[@CR7]^. MID1 acts as an E3 ubiquitin ligase and promotes the ubiquitin-dependent degradation of PP2A^[@CR8]^. Therefore, MID1 is a negative regulator of PP2A activity and thus inhibition of the MID1-PP2A complex is a promising approach to activate PP2A, and thereby induce its activity towards its target protein tau. In line with this, we have shown previously that the anti-diabetic drug metformin is capable of dephosphorylating tau at AD-relevant phospho-sites by interfering with the assembly of the MID1-PP2A-complex^[@CR7]^. Upon metformin treatment, the MID1-dependent degradation of PP2Ac is inhibited, resulting in increased PP2A activity and dephosphorylation of tau at AD specific sites^[@CR7]^. Besides regulating PP2A activity, MID1 also regulates the activity of the PP2A opposing kinase mTOR^[@CR9]^. Both enzymes, PP2A and mTOR, play a crucial role in the regulation of translation initiation by the eukaryotic initiation factor (eIF) complex. In detail, in absence of mTOR, a negative regulatory protein complex containing 4E-BP1 in association with eIF4E binds to the 5′ end of the mRNA and inhibits translation. To activate translation mTOR phosphorylates 4E-BP1, thereby releasing its inhibitory action and allowing a heterotrimeric complex containing eIF4E, eIF4A, and eIF4G to assemble at the 5′ end of the mRNA. At the same time, mTOR also phosphorylates and thereby activates p70 S6 kinase (S6K). S6K in turn phosphorylates and thereby activates its downstream targets eIF4B and S6. S6 is part of the small ribosomal subunit (40S). eIF3 is a multi-subunit protein that recruits 40S to the mRNA. Once associated with the mRNA, 40S starts scanning towards the ATG start codon. Upon start codon recognition, the large ribosomal subunit (60S) binds and, together with 40S, forms the translationally competent ribosome. The eIF complex is released from the mRNA and translation starts^[@CR10]^. PP2A and mTOR control translation by regulating the phosphorylation of 4E-BP1 and S6K. MID1 binds to GC-rich mRNAs and recruits its interacting proteins, including S6K and S6^[@CR11],[@CR12]^. By regulating the activity of both PP2A and mTOR, MID1 controls the translation of mRNAs bound to the MID1 complex^[@CR11]--[@CR14]^.

In this study we asked if MID1, besides its regulatory action on phospho-tau, could also affect APP. We show here a so far unknown connection between MID1 and APP: MID1 binds to the APP mRNA and regulates its translation. The underlying mode of action of MID1 involves the mTOR-dependent translation initiation pathway. Furthermore, we used metformin, a compound that we had shown previously to interfere with the MID1 complex and inactivate translation of MID1-target mRNAs^[@CR7],[@CR14],[@CR15]^, for a chronic treatment of an AD mouse model at a progressed state of disease. Our data show that metformin treatment decreases the protein levels of APP and consequently Aβ. This together with our previous observation that disassembly of the MID1 protein complex by metformin also decreases tau-phosphorylation^[@CR7]^, makes the MID1 protein complex a particularly interesting drug target for treating AD.

Results {#Sec2}
=======

Translation of APP is regulated by MID1 {#Sec3}
---------------------------------------

To investigate if the APP mRNA is regulated by the MID1-PP2A complex, we first tested if MID1 is able to bind to APP mRNA. For this we performed RNA-immunoprecipitations. Primary cortical neurons of wildtype mice were transfected with FLAG-MID1. After UV-crosslinking FLAG-MID1 was purified and MID1-bound mRNAs were isolated from the immunoprecipitates. As negative control an immunoprecipitation using unspecific IgGs was performed. RT-PCRs clearly showed the presence of APP mRNA in the MID1-immunoprecipitates (Fig. [1a](#Fig1){ref-type="fig"}).Fig. 1APP is a MID1 target mRNA**a** RNA immunoprecipitation. Primary neurons were transfected with MID1-FLAG. Afterwards MID1-mRNPs were purified by immunoprecipitation (IP FLAG) and MID1-bound mRNAs were analyzed for the presence of APP mRNA using RT-PCR. Unspecific IgG beads (IgG) were used as negative control. 5 µl of the PCR product were analyzed on a 1% agarose gel. **b** Inhibition of the MID1 complex reduces APP protein level. Primary cortical neurons were treated with a peptide that mimics the MID1-α4 binding site and thus outcompetes MID1 (GSK'364A). A mutant peptide was used as negative control (GSK'365A). APP protein levels were analyzed on western blots using APP-specific antibodies. β-actin was detected as loading control. A representative blot of *n* = 3 is shown. Graphs show quantification of western blots, mean values  ± SEM. \**p* \< 0.05. **c** Relative APP mRNA expression was measured in cells treated as in **b** by means of real-time PCR. Columns represent mean values ± SEM. *n* = 3. APP amyloid precursor protein

In previous studies we showed that binding of the MID1-complex to its target mRNAs induces protein translation from the respective mRNA^[@CR12],[@CR15],[@CR16]^. Therefore, we asked if the observed binding between APP mRNA and MID1 leads to an induction of APP translation. To test this we performed an experiment in primary cortical neurons with a peptide that mimics the binding sequence between MID1 and the α4-PP2A complex and therefore specifically outcompetes MID1. Depletion of MID1 led to a significant reduction of APP protein as shown on a western blot (Fig. [1b](#Fig1){ref-type="fig"}). Of note, the mRNA level of APP did not change significantly (Fig. [1c](#Fig1){ref-type="fig"}), which is in line with an inhibition at the protein synthesis level.

MID1 regulates APP translation by interacting with the mTOR-dependent translation initiation pathway {#Sec4}
----------------------------------------------------------------------------------------------------

As we have shown previously, the MID1-complex regulates translation in concert with mTOR. To identify at which exact step of the mTOR-dependent translation initiation MID1 functions, we analyzed proteins that bind to MID1. For this we performed an immunoprecipitation of FLAG-MID1 and analyzed all MID1-bound proteins by mass spectrometry. As expected, we detected several members of the mTOR-translation initiation cascade (Fig. [2a](#Fig2){ref-type="fig"} and Table [1](#Tab1){ref-type="table"}), several of which we validated on a western blot of FLAG-MID1-immunoprecipitates using specific antibodies (Fig. [2b](#Fig2){ref-type="fig"}). Interestingly, all MID1-bound proteins identified here were proteins of the mTOR-dependent translation pathway that act downstream of mTOR as well as S6K and 4E-BP, suggesting that MID1 regulates the mTOR-dependent translation by acting on either the eIFs or the ribosome. Thus, in a second set of experiments we added EDTA during the co-immunoprecipitation. EDTA dissociates ribosomal particles^[@CR17]^. While binding of most of the identified proteins to MID1 was abolished by the treatment, RPLP0, a member of the large subunit of the ribosome remained attached to MID1 (Fig. [2c](#Fig2){ref-type="fig"}). Since all of the proteins identified by mass spectrometry bind RNA in general, their presence in the MID1-immunoprecipitate may be explained by RNA-mediated indirect binding rather than by direct protein-protein interaction. To test which of the identified proteins bind to MID1 independent of RNA, we performed co-immunoprecipitation experiments in the presence or absence of RNase. Binding of the identified eIF proteins to MID1 was abolished by RNase treatment, while RPLP0, RPL5, and RPS3 remained attached to MID1 (Fig. [2d](#Fig2){ref-type="fig"}). These data suggest that MID1 directly binds to the ribosome to stimulate mTOR-dependent translation. In line with a MID1-mTOR dependent translation of APP, application of an mTOR inhibitor reduced APP translation both in an in vitro translation assay (Fig. [2e](#Fig2){ref-type="fig"}) as well as in primary neurons (Fig. [2f](#Fig2){ref-type="fig"}).Fig. 2MID1 is connected to the mTOR-dependent translation initiation pathway**a** Identification of the MID1-interactome. MID1-FLAG was expressed in HEK293T cells and MID1-complexes were purified by immunoprecipitation. MID1-binding proteins were identified by mass spectrometry. The mTOR-dependent translation initiation pathway is shown and the number of proteins identified belonging either to the eukaryotic translation initiation factor complex (eIF complex) or the ribosome are indicated. **b** Validation of the mass spectrometry results shown in **a** and Table [1](#Tab1){ref-type="table"}. MID1-FLAG was expressed in HEK293T cells and MID1-complexes were purified by immunoprecipitation (IP FLAG). As negative control, unspecific IgG agarose beads were used (IgG). Immunoprecipitates were analyzed on western blots using specific antibodies to detect MID1-FLAG, eIF3A, eIF4G, RPLP0, RPL5, RPS3. **c** Effect of ribosome disassembly on the composition of the MID1-complex. MID1-FLAG was expressed in HEK293T cells and immunopurified (IP FLAG) in the presence or absence of high concentrations of EDTA. Immunoprecipitates were analyzed on western blots using specific antibodies for MID1-FLAG, eIF3A, RPLP0, RPL5, RPS3. **d** To analyze the MID1-complex composition and its dependency on RNA, MID1-FLAG was expressed in HEK293T cells and immunopurified (IP FLAG) in the presence or absence of RNAse. As negative control, unspecific IgG agarose beads were used (IgG). Immunoprecipitates were analyzed on western blots using specific antibodies for MID1-FLAG, eIF3A, eIF4G, RPLP0, RPL5, RPS3. **e**, **f** mTOR regulates translation of APP. **e** In vitro translation of in vitro transcribed APP-mRNA tagged to luciferase in the presence or absence of the mTOR-inhibitor temsirolimus. The level of translated luciferase reporter was measured in a luciferase assay. Columns represent mean values ± SEM. *n* = 3. \**p* \< 0.01. **f** Primary neurons were treated with the mTOR-inhibitor temsirolimus. Protein extracts were analyzed on western blots, detecting APP and β-actin as loading control. Graph shows quantification of western blots, mean values ± SEM. *n* = 3. \**p* \< 0.01. APP amyloid precursor proteinTable 1Statistical analysis of proteins identified mass spectrometry analysis of MID1 immunoprecipitatesProtein nameGene IDLog2 ratio*P*-valueATP-binding cassette sub-family D member 3ABCD32.75E+012.04E-03ATP-binding cassette sub-family F member 2ABCF22.88E+015.96E-04Apoptotic chromatin condensation inducer in the nucleusACIN12.72E+011.39E-02Aldehyde dehydrogenase X, mitochondrialALDH1B12.62E+013.61E-04Mitochondrial 10-formyltetrahydrofolate dehydrogenaseALDH1L22.66E+011.97E-02THO complex subunit 4ALYREF2.99E+017.55E-04Serine/threonine-protein phosphatase 6 reg. ankyrin repeat subunit AANKRD282.63E+011.85E-02Coatomer subunit deltaARCN12.65E+012.36E-02Activating signal cointegrator 1 complex subunit 3ASCC32.59E+017.96E-03ATPase family AAA domain-containing protein 3AATAD3A1.77E+003.98E-02Sodium/potassium-transporting ATPase subunit alpha-1ATP1A12.72E+014.39E-04Ribosome biogenesis protein BMS1 homologBMS12.90E+018.92E-03Ribosome biogenesis protein BRX1 homologBRIX12.68E+011.41E-02Caprin-1CAPRIN12.80E+015.88E-03Coiled-coil domain-containing protein 124CCDC1242.94E+011.91E-04T-complex protein 1 subunit gammaCCT32.63E+014.86E-02T-complex protein 1 subunit epsilonCCT52.64E+011.42E-03Cell division cycle 5-like proteinCDC5L3.04E+013.51E-03Centrosomal protein of 170 kDaCEP1702.71E+012.53E-03Chromatin target of PRMT1 proteinCHTOP2.81E+013.45E-02CLIP-associating protein 2CLASP22.74E+014.83E-03Methylosome subunit pIClnCLNS1A2.97E+012.16E-03Coatomer subunit gamma-2COPG22.59E+012.98E-04Coronin-1CCORO1C3.03E+012.00E-02Cleavage and polyadenylation specificity factor subunit 6CPSF62.93E+014.13E-03Cleavage and polyadenylation specificity factor subunit 7CPSF72.73E+012.20E-03Probable ATP-dependent RNA helicase DDX17DDX173.22E+011.28E-02Probable ATP-dependent RNA helicase DDX20DDX202.73E+012.81E-02Nucleolar RNA helicase 2DDX213.01E+018.42E-03Probable ATP-dependent RNA helicase DDX23DDX232.93E+014.58E-03ATP-dependent RNA helicase DDX3XDDX3X2.66E+015.42E-04Probable ATP-dependent RNA helicase DDX41DDX412.73E+014.88E-03Probable ATP-dependent RNA helicase DDX5DDX52.97E+011.38E-02ATP-dependent RNA helicase DDX50DDX502.65E+015.75E-03Putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX15DHX152.76E+016.67E-03Putative ATP-dependent RNA helicase DHX30DHX302.99E+011.03E-02ATP-dependent RNA helicase ADHX97.63E+004.50E-03Elongation factor 2EEF24.68E+008.14E-03116 kDa U5 small nuclear ribonucleoprotein componentEFTUD23.04E+016.54E-03Eukaryotic translation initiation factor 3 subunit AEIF3A3.34E+012.89E-04Eukaryotic translation initiation factor 3 subunit BEIF3B3.19E+016.22E-03Eukaryotic translation initiation factor 3 subunit CEIF3C3.23E+011.43E-03Eukaryotic translation initiation factor 3 subunit DEIF3D3.01E+011.72E-03Eukaryotic translation initiation factor 3 subunit EEIF3E3.15E+012.60E-03Eukaryotic translation initiation factor 3 subunit FEIF3F3.08E+019.00E-03Eukaryotic translation initiation factor 3 subunit GEIF3G2.99E+011.64E-04Eukaryotic translation initiation factor 3 subunit IEIF3I3.07E+014.95E-03Eukaryotic translation initiation factor 3 subunit JEIF3J2.75E+012.97E-04Eukaryotic translation initiation factor 3 subunit KEIF3K2.75E+014.35E-02Eukaryotic translation initiation factor 3 subunit LEIF3L3.20E+011.62E-03Eukaryotic translation initiation factor 3 subunit MEIF3M3.06E+012.52E-02Eukaryotic translation initiation factor 3 subunit HEIF3S32.98E+014.34E-03Eukaryotic initiation factor 4A-IEIF4A12.82E+011.28E-02Eukaryotic initiation factor 4A-IIIEIF4A32.66E+012.37E-02Eukaryotic translation initiation factor 4BEIF4B3.07E+011.05E-02Eukaryotic translation initiation factor 6EIF62.71E+011.74E-02EmerinEMD2.73E+011.99E-02Erlin-2ERLIN22.81E+017.54E-03Exosome component 10EXOSC102.76E+013.45E-03Exosome complex component RRP45EXOSC92.59E+012.53E-02Constitutive coactivator of PPAR-gamma-like protein 1FAM120A2.74E+011.36E-02Phenylalanine\--tRNA ligase alpha subunitFARSA2.78E+017.54E-03Phenylalanine\--tRNA ligase beta subunitFARSB2.78E+011.17E-0240S ribosomal protein S30FAU2.85E+012.31E-03Protein furry homolog-likeFRYL3.02E+012.54E-02Gem-associated protein 4GEMIN42.71E+012.53E-03Guanine nucleotide-binding protein subunit beta-2-like 1GNB2L13.25E+013.47E-04Nucleolar GTP-binding protein 2GNL22.75E+017.11E-03Guanine nucleotide-binding protein-like 3GNL32.69E+014.03E-04Golgin subfamily A member 3GOLGA32.93E+013.96E-03General transcription factor 3C polypeptide 2GTF3C22.75E+013.97E-03General transcription factor 3C polypeptide 3GTF3C32.57E+013.56E-02General transcription factor 3C polypeptide 4GTF3C42.70E+012.46E-03Nucleolar GTP-binding protein 1GTPBP42.87E+011.26E-02Histone H2BHIST1H2BN2.99E+011.62E-02Heterogeneous nuclear ribonucleoproteins C1/C2HNRNPC3.08E+013.22E-04Heterogeneous nuclear ribonucleoprotein D0HNRNPD2.60E+012.60E-02Heterogeneous nuclear ribonucleoprotein FHNRNPF2.74E+014.67E-03Heterogeneous nuclear ribonucleoprotein KHNRNPK2.96E+019.43E-04Heterogeneous nuclear ribonucleoprotein MHNRNPM6.56E+001.98E-02Heterogeneous nuclear ribonucleoprotein RHNRNPR2.99E+014.29E-03Heterogeneous nuclear ribonucleoprotein UHNRNPU3.23E+012.34E-03Isoleucine\--tRNA ligase, cytoplasmicIARS2.72E+013.12E-03Insulin-like growth factor 2 mRNA-binding protein 1IGF2BP13.18E+011.09E-03Insulin-like growth factor 2 mRNA-binding protein 3IGF2BP32.81E+011.22E-02Interleukin enhancer-binding factor 2ILF23.10E+011.08E-02Interleukin enhancer-binding factor 3ILF33.27E+012.99E-03Importin-8IPO82.74E+011.30E-02Insulin receptor substrate 4IRS41.33E+003.38E-03Influenza virus NS1A-binding proteinIVNS1ABP3.33E+013.05E-03Tyrosine-protein kinase JAK1JAK12.88E+014.64E-03BTB/POZ domain-containing protein KCTD17KCTD172.96E+011.23E-02BTB/POZ domain-containing protein KCTD5KCTD52.96E+013.67E-04Kinesin-like protein KIF11KIF111.48E+001.25E-03La-related protein 1LARP13.17E+019.37E-04La-related protein 4LARP42.86E+017.22E-03La-related protein 4BLARP4B2.65E+018.21E-03LIM domain and actin-binding protein 1LIMA12.98E+017.34E-03Leucine-rich PPR motif-containing protein, mitochondrialLRPPRC2.63E+018.82E-03Putative RNA-binding protein Luc7-like 2LUC7L23.00E+013.39E-03Luc7-like protein 3LUC7L32.81E+015.20E-03Microtubule-associated protein 1BMAP1B3.01E+013.76E-03Serine/threonine-protein kinase MARK2MARK22.60E+013.76E-03Methionine\--tRNA ligase, cytoplasmicMARS2.62E+011.62E-03Matrin-3MATR32.87E+011.32E-03DNA replication licensing factor MCM7MCM72.83E+018.19E-03E3 ubiquitin-protein ligase Midline-1MID13.76E+013.26E-04Putative helicase MOV-10MOV102.77E+012.49E-0228S ribosomal protein S17, mitochondrialMRPS172.91E+016.96E-0328S ribosomal protein S22, mitochondrialMRPS222.74E+014.69E-0328S ribosomal protein S25, mitochondrialMRPS252.71E+011.14E-0228S ribosomal protein S27, mitochondrialMRPS272.64E+013.48E-02Protein LYRICMTDH2.72E+011.03E-02Myb-binding protein 1AMYBBP1A2.90E+011.44E-04Myosin-10MYH101.13E+002.28E-02Myosin-9MYH92.92E+014.78E-03Unconventional myosin-IbMYO1B2.71E+012.88E-02Nicotinamide phosphoribosyltransferaseNAMPT2.75E+018.55E-03Nucleosome assembly protein 1-like 1NAP1L12.57E+017.18E-03Nuclear cap-binding protein subunit 1NCBP12.81E+014.89E-04NucleolinNCL2.86E+016.74E-03Nucleolar complex protein 4 homologNOC4L2.80E+018.27E-03Probable 28S rRNA (cytosine(4447)-C(5))-methyltransferaseNOP22.62E+015.08E-03Cleavage and polyadenylation specificity factor subunit 5NUDT212.96E+016.21E-04OTU domain-containing protein 4OTUD42.74E+011.45E-03Prolyl 4-hydroxylase subunit alpha-1P4HA12.79E+014.44E-03Proliferation-associated protein 2G4PA2G43.08E+017.55E-03Polyadenylate-binding protein 1PABPC13.23E+012.17E-03Polyadenylate-binding protein 4PABPC43.22E+012.78E-03Programmed cell death protein 4PDCD42.94E+018.37E-03Proline-, glutamic acid- and leucine-rich protein 1PELP12.66E+019.09E-03Serine/threonine-protein phosphatase PGAM5, mitochondrialPGAM52.86E+013.52E-03Protein arginine N-methyltransferase 5PRMT53.54E+016.16E-04Pre-mRNA-processing factor 19PRPF193.02E+013.67E-03U4/U6 small nuclear ribonucleoprotein Prp3PRPF32.70E+011.69E-02U4/U6 small nuclear ribonucleoprotein Prp31PRPF312.97E+018.19E-04U4/U6 small nuclear ribonucleoprotein Prp4PRPF42.64E+013.83E-03Pre-mRNA-processing factor 6PRPF62.98E+016.12E-03Pre-mRNA-processing-splicing factor 8PRPF83.11E+013.06E-03Ribose-phosphate pyrophosphokinase 1PRPS15.58E+003.60E-03Ribose-phosphate pyrophosphokinase 2PRPS22.93E+011.56E-02Phosphoribosyl pyrophosphate synthase-associated protein 1PRPSAP13.05E+018.50E-03Phosphoribosyl pyrophosphate synthase-associated protein 2PRPSAP23.25E+012.15E-04Protein PRRC2APRRC2A2.85E+018.43E-03Protein PRRC2CPRRC2C2.97E+012.05E-0226S protease regulatory subunit 4PSMC12.97E+015.78E-0326S protease regulatory subunit 7PSMC23.07E+018.06E-0426S protease regulatory subunit 6APSMC32.89E+015.50E-0326S protease regulatory subunit 6BPSMC41.19E+001.54E-0226S protease regulatory subunit 8PSMC54.55E+003.71E-0426S protease regulatory subunit 10BPSMC62.84E+011.52E-0326S proteasome non-ATPase regulatory subunit 1PSMD12.97E+012.12E-0326S proteasome non-ATPase regulatory subunit 10PSMD102.85E+012.02E-0226S proteasome non-ATPase regulatory subunit 11PSMD113.02E+011.94E-0226S proteasome non-ATPase regulatory subunit 12PSMD122.90E+014.18E-0326S proteasome non-ATPase regulatory subunit 13PSMD132.95E+013.11E-0326S proteasome non-ATPase regulatory subunit 14PSMD142.80E+011.85E-0326S proteasome non-ATPase regulatory subunit 2PSMD22.15E+004.38E-0326S proteasome non-ATPase regulatory subunit 3PSMD33.04E+011.48E-0426S proteasome non-ATPase regulatory subunit 4PSMD42.79E+011.70E-0426S proteasome non-ATPase regulatory subunit 6PSMD62.96E+019.65E-0326S proteasome non-ATPase regulatory subunit 7PSMD73.75E+001.13E-0226S proteasome non-ATPase regulatory subunit 8PSMD82.75E+011.56E-03Poly(U)-binding-splicing factor PUF60PUF602.75E+019.95E-04Pyrroline-5-carboxylate reductasePYCR12.55E+013.49E-03RNA-binding protein 10RBM103.30E+014.88E-04RNA-binding protein 14RBM142.94E+016.57E-03RNA-binding protein 25RBM252.75E+017.71E-03RNA-binding protein 26RBM262.63E+013.79E-02RNA-binding protein 27RBM272.70E+011.20E-02RNA-binding protein 28RBM282.63E+015.02E-03RNA-binding motif protein, X chromosomeRBMX3.01E+018.90E-03RNA 3-terminal phosphate cyclase-like proteinRCL12.65E+011.64E-03Reticulocalbin-2RCN22.73E+012.67E-03Replication factor C subunit 3RFC32.62E+012.34E-02Telomere-associated protein RIF1RIF13.04E+019.16E-03Serine/threonine-protein kinase RIO1RIOK13.02E+013.05E-03RING finger protein 219RNF2192.94E+012.50E-03RNA-binding protein 39RNPC22.86E+018.92E-0360S ribosomal protein L10RPL103.26E+017.84E-0360S ribosomal protein L10aRPL10A3.22E+012.24E-0260S ribosomal protein L11RPL113.19E+011.04E-0360S ribosomal protein L12RPL123.18E+016.43E-0360S ribosomal protein L13RPL133.30E+014.30E-0460S ribosomal protein L13aRPL13A3.17E+012.25E-0360S ribosomal protein L14RPL143.07E+017.88E-0460S ribosomal protein L15RPL155.67E+008.90E-0360S ribosomal protein L17RPL173.16E+014.69E-0460S ribosomal protein L18RPL183.28E+011.68E-0360S ribosomal protein L18aRPL18A3.24E+012.10E-03Ribosomal protein L19RPL193.26E+014.36E-0360S ribosomal protein L21RPL213.11E+011.99E-0360S ribosomal protein L22RPL223.05E+011.47E-0360S ribosomal protein L22-like 1RPL22L12.70E+016.60E-0360S ribosomal protein L23RPL233.09E+014.70E-0360S ribosomal protein L23aRPL23A3.24E+011.26E-0360S ribosomal protein L24RPL243.03E+011.24E-0360S ribosomal protein L26RPL263.24E+011.20E-0360S ribosomal protein L27RPL273.18E+013.06E-0360S ribosomal protein L27aRPL27A3.06E+015.33E-0460S ribosomal protein L28RPL283.22E+016.23E-0460S ribosomal protein L29RPL293.19E+013.76E-0460S ribosomal protein L3RPL37.15E+006.72E-0360S ribosomal protein L30RPL303.04E+012.06E-0360S ribosomal protein L31RPL313.15E+013.12E-0460S ribosomal protein L32RPL323.18E+013.51E-0460S ribosomal protein L34RPL342.90E+014.73E-0360S ribosomal protein L35RPL353.13E+011.43E-0260S ribosomal protein L35aRPL35A3.14E+012.01E-0260S ribosomal protein L36RPL363.02E+011.49E-0260S ribosomal protein L36aRPL36A2.97E+015.51E-0460S ribosomal protein L37aRPL37A3.07E+011.05E-0460S ribosomal protein L38RPL382.90E+013.49E-0260S ribosomal protein L4RPL43.36E+011.82E-0360S ribosomal protein L5RPL53.26E+016.62E-0360S ribosomal protein L6RPL66.39E+009.35E-0360S ribosomal protein L7RPL73.33E+012.21E-0360S ribosomal protein L7aRPL7A8.22E+001.74E-0360S ribosomal protein L8RPL83.33E+019.73E-0460S ribosomal protein L9RPL93.06E+011.10E-0460S acidic ribosomal protein P0RPLP03.23E+012.18E-0360S acidic ribosomal protein P2RPLP22.87E+014.32E-0340S ribosomal protein S10RPS103.21E+011.86E-0340S ribosomal protein S11RPS113.24E+011.88E-0340S ribosomal protein S12RPS123.14E+014.05E-0440S ribosomal protein S13RPS133.22E+011.60E-0340S ribosomal protein S14RPS143.15E+014.92E-0440S ribosomal protein S15RPS153.15E+013.33E-0240S ribosomal protein S15aRPS15A3.19E+011.70E-0340S ribosomal protein S16RPS163.24E+011.08E-0340S ribosomal protein S17RPS173.19E+011.78E-0340S ribosomal protein S18RPS188.03E+007.90E-0940S ribosomal protein S19RPS193.22E+011.65E-0340S ribosomal protein S2RPS23.28E+011.71E-0340S ribosomal protein S20RPS203.21E+014.89E-0440S ribosomal protein S21RPS212.88E+012.47E-0340S ribosomal protein S23RPS233.25E+011.31E-0340S ribosomal protein S24RPS243.00E+011.10E-0440S ribosomal protein S25RPS253.14E+015.19E-0340S ribosomal protein S26RPS263.08E+012.54E-0240S ribosomal protein S27RPS273.00E+013.65E-0340S ribosomal protein S3RPS33.28E+013.26E-0340S ribosomal protein S3aRPS3A3.30E+014.75E-0440S ribosomal protein S4, X isoformRPS4X6.65E+002.28E-0340S ribosomal protein S6RPS63.18E+012.28E-0340S ribosomal protein S7RPS73.28E+011.99E-0240S ribosomal protein S8RPS83.24E+013.63E-0340S ribosomal protein S9RPS93.31E+013.94E-0340S ribosomal protein SARPSA3.32E+011.29E-03Ribosome-binding protein 1RRBP12.84E+013.20E-02RRP12-like proteinRRP122.58E+011.13E-02Ribosomal L1 domain-containing protein 1RSL1D12.69E+011.56E-02U4/U6.U5 tri-snRNP-associated protein 1SART12.91E+011.18E-04Splicing factor, arginine/serine-rich 15SCAF42.74E+011.68E-02Protein SDA1 homologSDAD12.64E+011.69E-02Plasminogen activator inhibitor 1 RNA-binding proteinSERBP13.28E+012.19E-02Splicing factor 3B subunit 1SF3B12.81E+018.87E-03Splicing factor 3B subunit 3SF3B32.72E+011.14E-02Superkiller viralicidic activity 2-like 2SKIV2L22.75E+018.05E-03U5 small nuclear ribonucleoprotein 200 kDa helicaseSNRNP2003.06E+015.98E-03U5 small nuclear ribonucleoprotein 40 kDa proteinSNRNP402.72E+011.41E-02Small nuclear ribonucleoprotein Sm D1SNRPD13.02E+011.48E-03Small nuclear ribonucleoprotein Sm D2SNRPD22.92E+012.94E-04Small nuclear ribonucleoprotein Sm D3SNRPD32.95E+011.93E-02Small nuclear ribonucleoprotein-associated proteins B and BSNRPN3.06E+014.62E-04Spectrin alpha chain, non-erythrocytic 1SPTAN13.41E+019.63E-04Spectrin beta chain, non-erythrocytic 1SPTBN13.41E+019.41E-05SRSF protein kinase 1SRPK12.94E+015.81E-03SRSF protein kinase 2SRPK22.60E+012.88E-02Serine/arginine repetitive matrix protein 1SRRM12.85E+011.46E-02Serrate RNA effector molecule homologSRRT2.57E+012.04E-03Serine/arginine-rich splicing factor 1SRSF12.74E+011.86E-04Serine/arginine-rich splicing factor 2SRSF22.69E+014.59E-02Serine/arginine-rich splicing factor 3SRSF32.87E+011.42E-03Double-stranded RNA-binding protein Staufen homolog 1STAU12.88E+011.18E-02Serine/threonine-protein kinase 38STK382.78E+012.59E-02SUN domain-containing protein 2SUN22.97E+016.35E-04Heterogeneous nuclear ribonucleoprotein QSYNCRIP2.82E+011.08E-02Very-long-chain enoyl-CoA reductaseTECR2.70E+014.59E-03Testis-expressed sequence 10 proteinTEX102.64E+011.64E-03THO complex subunit 2THOC22.53E+011.37E-02Tight junction protein ZO-2TJP22.65E+016.69E-03Transmembrane protein 33TMEM332.74E+011.11E-02Tropomodulin-3TMOD32.63E+014.62E-03TRMT1-like proteinTRMT1L2.82E+019.34E-03Tubulin beta-3 chainTUBB32.57E+015.04E-04Tubulin beta-4A chainTUBB4A2.61E+012.90E-02Splicing factor U2AF 35 kDa subunitU2AF12.90E+017.02E-03Splicing factor U2AF 65 kDa subunitU2AF22.98E+014.30E-03U2 snRNP-associated SURP motif-containing proteinU2SURP2.78E+011.78E-05E3 ubiquitin-protein ligase UBR5UBR52.78E+012.75E-02U4/U6.U5 tri-snRNP-associated protein 2USP392.88E+012.14E-02Transitional endoplasmic reticulum ATPaseVCP2.80E+017.61E-05VimentinVIM1.35E+002.08E-02Methylosome protein 50WDR773.30E+012.27E-02Exportin-TXPOT2.64E+017.27E-03Nuclease-sensitive element-binding protein 1YBX13.07E+013.00E-03YTH domain-containing protein 1YTHDC12.78E+018.82E-03YTH domain-containing family protein 2YTHDF21.60E+003.42E-02Zinc finger CCCH domain-containing protein 18ZC3H182.79E+011.14E-02Zinc finger CCCH-type antiviral protein 1ZC3HAV12.79E+011.27E-02Zinc finger protein 622ZNF6222.75E+011.14E-02Log2 ratio and *p*-values were calculated using measured protein intensities, i.e. eXtracted Ion Current (XIC) of all isotopic clusters associated with the identified amino acid sequence. Log2 ratio was calculated from the intensity sum of samples/ controls. *p*-values are the result of a two-sided t-test, samples vs. control. In cases where intensities had been measured in 2 (out of 3) replicates, the third intensity value was added through imputation. If no intensity could be measured in all 3 replicates, the intensities were set from 0 to 1 in order to still be able to calculate a ratio (same applies to cases where only 1 intensity could be measured)

Metformin reduces APP protein and APP cleavage products {#Sec5}
-------------------------------------------------------

To target MID1 we decided to use metformin, a compound that we had shown previously to interfere with the MID1 complex and inactivate translation of MID1-target mRNAs^[@CR7],[@CR14],[@CR15]^. In line with what we have observed for other MID1-target mRNAs, metformin treatment of primary cortical neurons also led to a reduction of APP protein in a dose-dependent manner (Fig. [3a](#Fig3){ref-type="fig"}).Fig. 3Disruption of the MID1-complex by metformin reduces APP protein levelPrimary neurons were treated with different doses of metformin. Protein extracts were analyzed on western blots detecting APP and β-actin as loading control. Graph shows quantification of western blots, mean values ± SEM. *n* = 3 \**p* \< 0.01. APP amyloid precursor protein

Finally, to investigate this effect in vivo, we chronically treated transgenic APP/PS1 mice with 5 g/l metformin in the drinking water for 8 months. In line with our data from primary neurons, full-length APP protein was significantly reduced in metformin treated mice (Fig. [4a](#Fig4){ref-type="fig"}), while APP mRNA levels were not significantly changed after metformin treatment (Fig. [4b](#Fig4){ref-type="fig"}). Together, these data suggest that the APP protein level was decreased in vivo on the translational level, which can be explained by inhibition of the MID1 complex. In line with an mTOR-MID1-PP2A-dependent down-regulation of APP in these mice, the phosphorylation of S6 was significantly reduced in brain lysates of these mice, as determined by western blots (Fig. [4c](#Fig4){ref-type="fig"}).Fig. 4Metformin reduces APP protein level in mice. Male and female APP/PS1 mice (age 12--13 months) were treated for 8 months with 5 g/l metformin in the drinking water**a** Protein extracts from brain tissue of these animals were analyzed on western blots detecting APP and β-actin as loading control. A representative blot of *n* = 3 males and *n* = 4 females is shown. Graphs show quantification of western blots, mean values ± SEM. \* = *p* \< 0.05. **b** Relative APP mRNA expression was measured in brain tissues described in **a** by means of real-time PCR. Columns represent mean values ± SEM. *n* = 5. **c** Protein extracts from brain tissue of these animals was analyzed on western blots, detecting phospho-S6 (p-S6), total S6 and β-actin as loading control. A representative blot of *n* = 6 is shown. Graphs show quantification of western blots, mean values ± SEM. \* = *p* \< 0.05

A reduction of APP should lead to a reduced Aβ plaque burden in the treated animals. To quantify this we first measured levels of Aβ on dot blots, showing that Aβ levels were significantly decreased in metformin treated animals (Fig. [5a](#Fig5){ref-type="fig"}). Second, in an ELISA measuring the levels of Aβ40 and Aβ42, a significant decrease of Aβ peptides was observed in both female and male mice (Fig. [5b](#Fig5){ref-type="fig"}). Of note, there was also a significant difference in Aβ levels between female and male mice. To investigate the Aβ plaque burden in the hippocampus, we performed Thioflavin-S stainings. In line with dot blot and ELISA experiments, thioflavin staining showed less aggregates in metformin treated animals (Fig. [5c](#Fig5){ref-type="fig"}). To test if metformin affects learning and memory, APP/PS1 mice that were treated with metformin were examined in behavioral tests. A significantly improved performance in the Morris water maze was observed in animals that were treated with metformin (Fig. [5d](#Fig5){ref-type="fig"}).Fig. 5Metformin reduces Aβ plaque burden in mice. Male and female APP/PS1 mice (age 12--13 months) were treated for 8 months with 5g/l metformin in the drinking water**a** Protein extracts from brain tissue of these animals was analyzed on dot blots detecting Aβ. Representative blots of *n* = 4 females and *n* = 3 males are shown. Graphs show quantification of dot blots, mean values ± SEM, the mean value of control animals was set to 100%. \**p* \< 0.05. **b** ELISA measurements of Aβ in brain tissues described in **a**. Columns represent mean values (pg/ml) ± SEM. *n* = 4 females, *n* = 3 males. \**p* \< 0.05. **c** Sagittal brain sections of mice were stained with Thioflavin-S for Aβ aggregates. Scale bar = 200 µm **d** Spatial learning and memory in the Morris water maze. Mice were trained on a hidden version of the Morris water maze. After completion of training, we performed a probe trial to test how accurately the animals had learned the location of the escape platform (target). The graph shows the number of crossings of the target location vs. averaged crossings of corresponding positions in the adjacent, non-target quadrants (reference). Shown are means ± SEM. *n* = 10 mice per group. \**p* \< 0.05

Besides regulating translation, mTOR is also a known regulator of autophagy. Therefore, in our in vivo set-up we cannot rule out that the observed reduction of Aβ could be at least partially due to increased clearance via autophagy. To address this, we analyzed the degradation of Aβ in SH-EP cells containing TAMRA-Aβ42 aggregates. Clearly, no increased degradation of Aβ was detectable in these cells, suggesting that metformin treatment does not induce autophageal degradation of Aβ (Fig. [6](#Fig6){ref-type="fig"}).Fig. 6Metformin treatment does not induce degradation of AβDetermination of cellular Aβ42 aggregate loads in SH-EP cells containing TAMRA-Aβ42 aggregates. Cells were treated with different amounts of metformin and Aβ42 aggregate load was quantified by automated fluorescence microscopy. Aggregates per cell were either quantified by the TAMRA-labeling or alternatively by immunofluorescence using the 6E10-Aβ-antibody. ECGC, a substance that was previously reported to remodel Aβ fibrils^[@CR32],\ [@CR33]^, was used as positive control. Graph show mean values ± SEM. *n* = 3. \**p* \< 0.001

In summary, all these data suggest that metformin inhibits the MID1-dependent translation of APP and thereby reduces Aβ plaque burden and improves cognitive impairments in an AD mouse model.

Discussion {#Sec6}
==========

In this study, we show a novel regulatory mechanism controlling the protein synthesis of APP: this mechanism involves the MID1 protein, which induces the translation of APP by regulating mTOR-eIF signaling. Disassembly of the MID1 protein complex by metformin reduces the protein production of APP. Furthermore, we show that chronic treatment of AD mice with metformin decreases the protein level of APP and its cleavage products, including Aβ. This together with our previous observation that disassembly of the MID1 protein complex by metformin also decreases tau-phosphorylation^[@CR7]^, makes MID1 a particularly interesting drug target for treating AD.

Among other effects, metformin induces PP2A activity by interfering with the assembly of the MID1-PP2A-complex^[@CR7]^. Although MID1 has an inhibitory effect on PP2A^[@CR8]^, it positively regulates mTOR^[@CR9]^. Therefore, metformin activates PP2A, while at the same time it suppresses mTOR. Decreased mTOR signalling results in activation of autophagy and decreased translation of mRNAs regulated by its downstream effectors S6K and 4E-BP1^[@CR21]^. The MID1 protein complex via PP2A and mTOR stimulates translation of mRNAs that are associated with this protein complex, some of which play a role in neurodegeneration^[@CR11]--[@CR13],[@CR16]^.

Here we identified APP mRNA as a novel binding partner of MID1, suggesting that the MID1 complex also induces its translation. Since the biguanide metformin interferes with the assembly of the MID1 protein complex, it thereby reduces translation of the APP mRNA, leading to decreased processing by the amyloidogenic pathway. This mode of action of metformin has also been shown for other mRNAs that are associated with the MID1-complex, including the androgen receptor (AR) and BACE1 mRNA^[@CR14],[@CR15]^. Furthermore, we report a so far unknown additional connection between MID1 and the mTOR-dependent translation initiation pathway: MID1 binds to RPLP0, a protein of the large ribosomal subunit. Metformin treatment interferes with the MID1-complex assembly and thus inhibits MID1-dependent translation^[@CR7],[@CR14],[@CR15]^. Overall, metformin seems to decrease translation of several MID1-PP2A-mTOR dependent mRNAs. However, since chronic administration of metformin is well tolerated in type 2 diabetes patients, this does not seem to be particularly deleterious. Additionally, both induction of autophagy and reduced protein translation are especially vital for the adult nervous system, since these processes control homeostasis of Aβ and phospho-tau^[@CR19],[@CR20]^. Therefore, we believe that reduced protein translation of several mRNAs regulated by MID1/PP2A/mTOR would be beneficial.

The use of metformin as a putative drug for treating AD has been discussed controversially^[@CR15],[@CR21]--[@CR27]^. While in some studies metformin treatment increased APP^[@CR27]^ or Aβ levels^[@CR24]^, other studies showed that metformin attenuated AD-like neuropathology for example by decreasing the level of the APP processing enzyme BACE1^[@CR15]^, or by decreasing tau hyperphosphorylation^[@CR7],[@CR25]^. This discrepancy can be explained by differences in the experimental set-up in the different studies. First, the effect of metformin seems to be dose- and time-dependent. For example, in cell culture models high doses of metformin (5--50 mM) or long incubation times result in an increased expression of APP and BACE1^[@CR24],[@CR27]^, while lower doses (1--2.5 mM) decrease BACE1 protein levels as well as APP cleavage products and tau phosphorylation^[@CR7],[@CR15],[@CR23]^. In wildtype mice treatment with 2 g/l metformin in the drinking water results in increased expression of BACE1 and APP as well as APP cleavage products^[@CR24],[@CR27]^, while treatment with 5 g/l reduces BACE1 protein expression^[@CR15]^ as well as tau-phosphorylation^[@CR7]^. Also the period of treatment seems to be important. Different to studies in which increased APP and BACE1 levels were detected^[@CR24],[@CR27]^, our study lasted over a treatment period of 8 months. Therefore, differences between acute and chronic pharmacological treatments could account for the observed effects. Of note, in our experiments we detected a significant difference in Aβ levels between female and male mice, with female mice having an increased Aβ burden compared to male mice. This observation is in line with previous findings, showing that female mice exhibit much higher γ-secretase activity in aged brain compared to male mice and therefore, Aβ plaque pathology in female mouse models of AD is increased compared to males^[@CR28]^. Interestingly, another study in which metformin had been used in a chronic treatment demonstrated that learning and memory were improved by metformin treatment in female mice, while it had an opposite effect in male mice^[@CR26]^. This shows that also the sex of the experimental animals used could account for different findings. Another important point is the age of the experimental animals in which the treatment was initiated. To our knowledge our study is the first study in which metformin treatment was initiated in aged mice displaying an already progressed state of the disease.

Taken together, our study shows that long-term treatment with metformin inhibits the MID1-dependent translation of APP and thus reduces Aβ plaque burden without any side effects for the animals. The administration of metformin for a prolonged period (8 months) started late in life and in an already progressed state of the disease. Therefore, our data represent the effects of metformin on biochemical and cognitive changes of the CNS in a progressed disease stage of AD. In addition, we could show in our previous work, that disassembly of the MID1 protein complex by metformin also decreases tau-phosphorylation^[@CR7]^, making the MID1 complex a particularly interesting target for treating all AD neuropathologies.

Materials and methods {#Sec7}
=====================

In vitro translation {#Sec8}
--------------------

To create an hAPP-Luciferase fusion construct, the human APP wild type splice variant 695 cDNA sequence was amplified by PCR from the pcDNA-hAPP695wt plasmid using primers APP-pGL3m-fwd and APP-pGL3m-rev (Table [2](#Tab2){ref-type="table"}), thereby creating HindIII and NcoI restriction sites, which were used to insert the amplified sequence into the pGL3m plasmid^[@CR11]^ 5′ of the firefly luciferase sequence. To enable in vitro transcription, a T7 site was inserted by PCR using primers T7-hAPP-ivts-fwd and pGL3--2258-ivts-rev (Table [2](#Tab2){ref-type="table"}). The resulting amplificate was phenol-chloroform purified and subjected to in vitro transcription using the RiboMAX^TM^ Large scale RNA production system-T7 (Promega, Mannheim, Germany) according to the manufacturer's instructions. In vitro transcribed RNA was phenol-chloroform purified and translated in vitro using the Flexi Rabbit Reticulocyte Lysate System (Promega) in presence or absence of inhibitors. Luciferase activity was quantified using the Firefly Luciferase Assay System (Promega) on a FLUOstar Omega 96-well plate reader (BMG Labtech, Ortenberg, Germany).Table 2Primer sequencesmAPP-RT-fwdCAC ATC GTG ATT CCT TAC CGmAPP-RT-revGTC TCA CAA ACA TCC ATC CGmGAPDH-RT-fwdGCA CAG TCA AGG CCG AGA ATmGAPDH-RT-revGCC TTC TCC ATG GTG GTG AAAPP-pGL3m-fwdTGC AAA AAG CTT GGC ATT CCG GTA CTG TTG GTA AAG CCAAPP-pGL3m-revCGT CTT CCA TGG CGC CTG GAC CGT TCT GCA TCT GCT CAA AGA ACT TGT AGG TT7-hAPP-ivts-fwdCGA AAT TAA TAC GAC TCA CTA TAG GGG TAA AGC CAC CAT GCT GCC CGG TTT GGC ACT GCpGL3-2258-ivts-revCCG CGC CCA CCG GAA GGA GCT GAC TGG

Immunoprecipitation {#Sec9}
-------------------

Cells have been authenticated by PCR-single-locus-technology (service by Eurofins (Ebersberg, Germany)) in December 2016. HEK293T cells were transfected with pCMV-MID1-Tag2A using PolyFect (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Untransfected cells were used as control. Cell pellets were lysed in TKM buffer (20 mM Tris pH 7.4, 100 mM KCl, 5 mM MgCl~2~, 0.5% NP40, 1 mM DTT, protease inhibitors) using a Precellys cell homogenizer. For pre-clearing, 200 µl of IgG-agarose beads were added to the lysates and incubated rotating for 30 min at 4 °C. The beads were pelleted for 5 min at 21,000 x g. Precleared lysates were then added to 200 µl anti-FLAG M1 Agarose Affinity Gel (Sigma-Aldrich/Merck, Darmstadt, Germany). After overnight rotation at 4 °C, the beads were washed 6 times and resuspended in 50 µl 1x SDS Buffer and boiled for 10 min at 95 °C. The proteins were then either identfied by mass spectrometry analysis or analyzed on a western blot. For ribosome disassembly, immunoprecipitation was performed in TKM buffer containing 40 mM EDTA. For RNase digest, the beads were washed three times after overnight incubation, anti-FLAG beads were split into two aliquots and resuspended in NEBuffer 3 (B7003S, New England Biolabs, Frankfurt, Germany). RNase If (M0243, New England Biolabs) was added to a final concentration of 500 U/ml to one immunoprecipitate and incubated for 45 min at 37 °C. Subsequently, beads were washed three times and treated as described above.

Mass spectrometry {#Sec10}
-----------------

The eluted proteins were concentrated into one band on an SDS-PAGE gel. The band was excised and the proteins contained were processed using an automated sample preparation setup^[@CR29]^. The generated peptides were purified on StageTips^[@CR30]^. Samples were measured on a Q-Exactive mass spectrometer (Thermo-Fisher, Waltham, MA, USA) coupled to a Proxeon nano-LC system (Thermo-Fisher) in data-dependent acquisition mode, selecting the top 10 peaks for HCD fragmentation. A 1h gradient (solvent A: 5% acetonitrile, 0.1% formic acid; solvent B: 80% acetonitrile, 0.1% formic acid) was applied for the samples using an in-house prepared nano-LC column (0.075 mM × 150 mM, 3 μm Reprosil C18, Dr. Maisch GmbH, Ammerbuch-Entringen, Germany). A volume of 2 μl sample was injected and peptides were eluted with 3 h gradients of 5--75% solvent B at flow rates of 0.25 μl/min. MS acquisition was performed at a resolution of 70,000 in the scan range from 300 to 1700 *m*/*z*. The normalized collision energy was set to 26 eV. The mass window for precursor ion selection was set to 2.0 *m*/*z*. The recorded spectra were analyzed using the MaxQuant software package (Version 1.3.0.5)^[@CR31]^ by matching the data to the Uniprot human database (downloaded on 06.05.2012) with a false discovery rate (FDR) of 1%.

Peptide treatments {#Sec11}
------------------

Murine primary cortical neurons were treated with 2.5 µM of a peptide that mimics the MID1-α4 binding site and thus outcompetes MID1 from binding to α4-PP2Ac. As control a mutant peptide was used. Peptides (GSK'364A and GSK'365A) containing a 29-residue sequence from α4 (AQAKVFGAGYPSLPTMTVSDWYEQHRKYG and AQAKVFGAGYPSLPTMTVSDWAEQHRKYG, respectively) with an N-terminal sequence derived from HIV-TAT protein (RKKRRQRRR) were supplied by Cambridge Research Biochemicals (Billingham, UK). They were synthesized using standard automated solid-phase peptide synthesis via the Fmoc/tBu strategy. Cleavage from the resin was performed using 95% trifluoroacetic acid. Crudes were purified by preparative high-performance liquid chromatography (HPLC), freeze dried and characterized by high-performance liquid chromatography (HPLC) and matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry.

In vivo treatments mice {#Sec12}
-----------------------

Male and female APP/PS1 (B6C3-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax) mice (age 12--13 months) were treated for 8 months with 5 g/l metformin in the drinking water with daily change of water and addition of fresh metformin. Water intake and body weight of the animals were monitored. After 8 months of treatment, animals were sacrificed and brains were snap-frozen in liquid nitrogen and broken up using a mortar. All procedures were in compliance with German Animal Protection Law and were approved by the competent authorities (Landesamt für Naturschutz und Verbraucherschutz Nordrhein-Westphalen; AZ 87--51.04.2011.A049/01).

Morris water maze {#Sec13}
-----------------

We assessed spatial learning and memory in the Morris water maze in APP/PS1 mice treated with metformin or vehicle control. The water pool (Med Associates) had a diameter of 1.2 m and was filled with opaque water (temperature: 24 °C). Mice received 6 daily training trials for 3 consecutive days on a hidden version of the Morris water maze (i.e., the maze contained an escape platform hidden underneath the water surface in a constant location of the pool). To evaluate the accuracy with which the animals had learned the position of the escape platform, we performed a probe trial (during which the platform was removed from the pool) once training was completed. Behavior of the animals was recorded using an automated tracking system (Ethovision XT, Noldus). We determined the number of crossings of the exact target location (i.e., where the platform was located during training) and compared it to the average crossings of analogous positions in the adjacent, non-target quadrants (reference).

Thioflavin-S staining {#Sec14}
---------------------

Sagittal brain sections were incubated in 1x TBS buffer containing 10% Triton X-100 and transferred onto glass slides. The slides were dried overnight at room temperature. Slides were washed 3 times for 3 min in distilled water, and incubated for 3 min in 0.1% Thioflavin-S staining solution (dissolved in 10% ethanol diluted in distilled water) in the dark. Sections were washed 3 times in distilled water and incubated for 20 min in 1% acetic acid in the dark. Slides were washed with tap water, cover-slipped with mounting medium (Thermo-Fisher), and stored in the dark at 4 °C.

Western blot {#Sec15}
------------

Brain samples were homogenized either in RIPA buffer (20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% NP-40, 1% sodium deoxycholate, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na~3~VO~4~, 1 μg/ml leupeptin) or in SDS PAGE buffer B (40 mM Tris-HCl pH 6.8, 4% Glycerol, 2% SDS, 0.01% bromophenolblue, 2 mM 2-mercaptoethanol), sonicated and boiled for 5 min at 95 °C. Proteins were analyzed on 10 or 12% SDS gels and blotted onto PVDF membranes (Roche, Mannheim, Germany). Blots were blocked in milk and incubated with the antibodies listed below.

Bands were densitometrically quantified using AIDA software v4.27 (Raytest, Straubenhardt, Germany).

Statistical analysis {#Sec16}
--------------------

Statistical analyses were performed using two-way ANOVA, as well as Student's t-test or Mann-Whitney test (two-tailed) for two-group comparisons, as appropriate.

Dot blot {#Sec17}
--------

Brain samples were homogenized in RIPA buffer. 50 µg total protein per well were loaded and proteins were transferred to a PVDF membrane using a HYBRI-DOT manifold. The aggregates on the membrane were detected by incubation with anti-beta-amyloid 6E10 antibodies (BioLegend, San Diego, CA, USA).

ELISA {#Sec18}
-----

ELISA assays to measure Aβ were performed using the Aβ40 / Aβ42 ELISA Kits (Life Technologies) according to the manufacturer's protocol.

Antibodies {#Sec19}
----------

The following antibodies were purchased from Cell Signaling (Leiden, Netherlands): S6 (\#2317), pS6 (\#4858), actin (\#4967), eIF3A (\#3411), eIF4G (\#2498), RPL5 (\#51345) and GAPDH (\#2118). FLAG-HRP (A8592) antibody was purchased from Sigma; RPLP0 (ab192866), RPS3 (\#128995), and APP (ab2071) from Abcam (Cambridge, UK), and anti-beta-amyloid 6E10 from BioLegend (803001).

Real-time PCR {#Sec20}
-------------

Total RNA was isolated using the RNeasy Plus Mini Kit (Qiagen). cDNA was synthesized using the TaqMan reverse transcription reagents kit (Applied Biosystems, Waltham, MA, USA) and real-time PCR was carried out using the SYBRGreen PCR master mix (Applied Biosystems). Primers used are listed in Table [2](#Tab2){ref-type="table"}.

RNA immunoprecipitation {#Sec21}
-----------------------

Murine primary cortical neurons were transfected with FLAG-tagged MID1 using Lipofectamine 2000 (Invitrogen Waltham, MA, USA). 48 h after transfection, cells were treated with or without 2.5 mM metformin and incubated another 24 h. After UV-crosslinking (200 mJ/cm^2^) cells were lysed in TKM buffer (20 mM Tris pH 7.4, 100 mM KCl, 5 mM MgCl~2~, Complete protease inhibitor cocktail (Roche), RNAse inhibitor, 0.2% NP40) and MID1 protein complexes were purified by immunoprecipitation using anti-FLAG M1 Agarose Affinity Gel (Sigma-Aldrich) or IgG-agarose (Sigma-Aldrich) as a negative control. Protein-bound mRNA was isolated after DNAse and proteinase K digestion by phenol-chloroform purification and analyzed by RT-PCR. Primers used are listed in Table [2](#Tab2){ref-type="table"}.

Automated fluorescence microscopy and determination of cellular Aβ42 aggregate loads {#Sec22}
------------------------------------------------------------------------------------

For fluorescent labeling of Aβ aggregates, 20 µM Aβ42 peptide stock solutions diluted in low salt buffer (10 mM NaCl, 1.9 KH~2~PO~4~, 8.1 mM K~2~HPO~4~, pH 7.4) were mixed with 5% Aβ42 peptides which have been N-terminally labeled with the fluorophore 5-Carboxytetramethylrhodamine (TAMRA) in solid-state peptide synthesis by AnsSpec, Fremont, USA. Then, mixed Aβ peptide solutions were aggregated at 37 °C for 18 h under 300 rpm constant agitation followed by sonication with a Sonic Dismembrator Model 120 from Fisher Scientific GmbH (Schwerte, Germany) at low intensity for 6 rounds of 10 s. SH-EP cells (DSMZ, Braunschweig, Germany) were cultured in DMEM (Gibco by Thermo-Fisher GmbH, Dreeich, Germany) containing 10% fetal bovine serum (FBS), 5% Glucose, 100 units/ml penicillin and streptomycin, respectively. Incubation was carried out at 37 °C with 5% (v/v) CO~2~. For Aβ42 aggregate internalization, cells were treated with 600 nM or 1 µM TAMRA-Aβ42 for 18 h. To ensure removal of free and surface-bound aggregates, Aβ containing medium was aspirated, cells were washed with phosphate-buffered saline (PBS), trypsinized and collected in fresh medium. Then, cells were seeded into 96-well cell culture plates and treated with different amounts of metformin for 6 h. Cells were fixed in 2% paraformaldehyde for 20 min at room temperature, followed by Nuclei staining with Hoechst (1:2500 Hoechst 33342, Sigma-Aldrich Chemie Gmbh Munich, Germany) and then washed twice with PBS, before fluorescent microscopy was performed in a Cellomics ArrayScan Hight-Content System (Thermo-Fisher) using an objective with 20-fold magnification. After image acquisition, automated data analysis was performed using ArrayScan VTI (700 Series, Thermo-Fisher). For quantification, individual cells were detected via Hoechst fluorescent signals (XT53, filter and dichroic-emitter pair) and total TAMRA fluorescent areas per cell (XT32, filter and dichroic-emitter pair) were measured and calculated from technical triplicates. Alternatively, Aβ was stained by immunofluorescence using the 6E10 antibody (BioLegend).
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